Screening  ||| S:0 E:10 ||| VBG
for  ||| S:10 E:14 ||| IN
BRCA1  ||| S:14 E:20 ||| NNP
and  ||| S:20 E:24 ||| CC
BRCA2  ||| S:24 E:30 ||| CD
mutations  ||| S:30 E:40 ||| NNS
in  ||| S:40 E:43 ||| IN
breast  ||| S:43 E:50 ||| JJ
cancer  ||| S:50 E:57 ||| NN
patients  ||| S:57 E:66 ||| NNS
from  ||| S:66 E:71 ||| IN
Mexico ||| S:71 E:77 ||| NNP
:  ||| S:77 E:79 ||| :
the  ||| S:79 E:83 ||| DT
public  ||| S:83 E:90 ||| JJ
health  ||| S:90 E:97 ||| NN
perspective  ||| S:97 E:109 ||| NN
Genetic  ||| S:109 E:117 ||| JJ
testing  ||| S:117 E:125 ||| NN
for  ||| S:125 E:129 ||| IN
mutations  ||| S:129 E:139 ||| NNS
in  ||| S:139 E:142 ||| IN
BRCA1  ||| S:142 E:148 ||| NNP
and  ||| S:148 E:152 ||| CC
BRCA2  ||| S:152 E:158 ||| NNP
has  ||| S:158 E:162 ||| VBZ
potentially  ||| S:162 E:174 ||| RB
important  ||| S:174 E:184 ||| JJ
public  ||| S:184 E:191 ||| JJ
health  ||| S:191 E:198 ||| NN
implications ||| S:198 E:210 ||| NNS
.  ||| S:210 E:212 ||| .
Through  ||| S:212 E:220 ||| IN
judicious  ||| S:220 E:230 ||| JJ
testing  ||| S:230 E:238 ||| NN
of  ||| S:238 E:241 ||| IN
women  ||| S:241 E:247 ||| NNS
believed  ||| S:247 E:256 ||| VBD
to  ||| S:256 E:259 ||| TO
be  ||| S:259 E:262 ||| VB
at  ||| S:262 E:265 ||| IN
high  ||| S:265 E:270 ||| JJ
risk  ||| S:270 E:275 ||| NN
for  ||| S:275 E:279 ||| IN
early-onset  ||| S:279 E:291 ||| JJ
breast  ||| S:291 E:298 ||| NN
cancer  ||| S:298 E:305 ||| NN
and  ||| S:305 E:309 ||| CC
for  ||| S:309 E:313 ||| IN
ovarian  ||| S:313 E:321 ||| JJ
cancer ||| S:321 E:327 ||| NN
,  ||| S:327 E:329 ||| ,
it  ||| S:329 E:332 ||| PRP
is  ||| S:332 E:335 ||| VBZ
possible  ||| S:335 E:344 ||| JJ
to  ||| S:344 E:347 ||| TO
identify  ||| S:347 E:356 ||| VB
highly-predisposed  ||| S:356 E:375 ||| JJ
women  ||| S:375 E:381 ||| NNS
prior  ||| S:381 E:387 ||| RB
to  ||| S:387 E:390 ||| TO
the  ||| S:390 E:394 ||| DT
development  ||| S:394 E:406 ||| NN
of  ||| S:406 E:409 ||| IN
cancer ||| S:409 E:415 ||| NN
.  ||| S:415 E:417 ||| .
Current  ||| S:417 E:425 ||| JJ
preventive  ||| S:425 E:436 ||| JJ
options  ||| S:436 E:444 ||| NNS
include  ||| S:444 E:452 ||| VBP
preventive  ||| S:452 E:463 ||| JJ
mastectomy ||| S:463 E:473 ||| NN
,  ||| S:473 E:475 ||| ,
preventive  ||| S:475 E:486 ||| JJ
oophorectomy ||| S:486 E:498 ||| NN
,  ||| S:498 E:500 ||| ,
tamoxifen  ||| S:500 E:510 ||| NN
and  ||| S:510 E:514 ||| CC
oral  ||| S:514 E:519 ||| JJ
contraceptives ||| S:519 E:533 ||| NNS
.  ||| S:533 E:535 ||| .
The  ||| S:535 E:539 ||| DT
ability  ||| S:539 E:547 ||| NN
to  ||| S:547 E:550 ||| TO
offer  ||| S:550 E:556 ||| VB
genetic  ||| S:556 E:564 ||| JJ
testing  ||| S:564 E:572 ||| NN
in  ||| S:572 E:575 ||| IN
Mexico  ||| S:575 E:582 ||| NNP
on  ||| S:582 E:585 ||| IN
a  ||| S:585 E:587 ||| DT
widespread  ||| S:587 E:598 ||| JJ
level  ||| S:598 E:604 ||| NN
is  ||| S:604 E:607 ||| VBZ
enhanced  ||| S:607 E:616 ||| VBN
if  ||| S:616 E:619 ||| IN
the  ||| S:619 E:623 ||| DT
common  ||| S:623 E:630 ||| JJ
founder  ||| S:630 E:638 ||| NN
mutations  ||| S:638 E:648 ||| NNS
in  ||| S:648 E:651 ||| IN
the  ||| S:651 E:655 ||| DT
two  ||| S:655 E:659 ||| CD
genes  ||| S:659 E:665 ||| NNS
can  ||| S:665 E:669 ||| MD
be  ||| S:669 E:672 ||| VB
discovered  ||| S:672 E:683 ||| VBN
or  ||| S:683 E:686 ||| CC
if  ||| S:686 E:689 ||| IN
the  ||| S:689 E:693 ||| DT
cost  ||| S:693 E:698 ||| NN
of  ||| S:698 E:701 ||| IN
genetic  ||| S:701 E:709 ||| JJ
sequencing  ||| S:709 E:720 ||| NN
is  ||| S:720 E:723 ||| VBZ
reduced ||| S:723 E:730 ||| VBN
.  ||| S:730 E:732 ||| .
It  ||| S:732 E:735 ||| PRP
is  ||| S:735 E:738 ||| VBZ
important  ||| S:738 E:748 ||| JJ
that  ||| S:748 E:753 ||| IN
a  ||| S:753 E:755 ||| DT
genetic  ||| S:755 E:763 ||| JJ
testing  ||| S:763 E:771 ||| NN
service  ||| S:771 E:779 ||| NN
be  ||| S:779 E:782 ||| VB
a  ||| S:782 E:784 ||| DT
multi-disciplinary  ||| S:784 E:803 ||| JJ
effort  ||| S:803 E:810 ||| NN
with  ||| S:810 E:815 ||| IN
co-ordinated  ||| S:815 E:828 ||| JJ
follow-up ||| S:828 E:837 ||| NN
.  ||| S:837 E:839 ||| .
